HIV Pathogenesis and Cure
HIV Pathogenesis and Cure
批准号:
9927061
负责人:
Thale Cross Jarvis
金额:
$1.74万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-02-03 至 2022-01-31
关键词:
AIDS preventionAcquired Immunodeficiency SyndromeAnimal ModelAntibodiesAreaBiologyBiology of HIV InfectionCellsCessation of lifeCollaborationsColoradoCommunitiesDevelopmentDisease ProgressionEducational workshopEmerging TechnologiesFosteringFutureGoalsHIVHIV InfectionsHIV vaccineHIV-1ImmuneImmunologistImmunologyIndividualIndustryInternationalJointsKnowledgeMethodologyOutcomePathogenesisPatientsPharmaceutical PreparationsPhysiciansResearchResearch PersonnelScientistStudentsT cell responseTherapeuticTranscriptional RegulationVirusVirus Replicationantiretroviral therapybaseclinical practiceimmune reconstitutionimprovedindustry partnerinterestlatent HIV reservoirmeetingsmortalitynew technologynext generationnovelpandemic diseaseposterspreventsymposiumtreatment strategyvirology
中文摘要
摘要
要求为题为“艾滋病毒发病机制和治疗”的Keystone专题讨论会提供支助,
Drs. Robert F.卡林?西利西亚诺货车林特和罗马斯·格勒兹乌纳斯。会议将在Keystone举行,
科罗拉多,2020年3月22日至26日。
人类免疫缺陷病毒1型(艾滋病毒)是一种全球性流行病的病因,死亡率非常高
据估计,到目前为止已有3500万人死亡。此外,还有3700万人目前生活在
艾滋病毒感染,并可能死于获得性免疫缺陷综合征(艾滋病),而不会终身
抗逆转录病毒疗法(ART)。最佳的ART可以阻止病毒复制,从而防止疾病进展,
使免疫系统得以重建然而,由于病毒的潜伏形式的持续存在,ART不是治愈性的。
这种潜在的形式是治疗的主要障碍,也是国际研究努力的主题。沿着
随着艾滋病疫苗的研制,针对艾滋病病毒潜伏库的研究是艾滋病研究的一个主要优先事项。
更好地了解艾滋病毒感染的基本生物学可能对艾滋病毒的治愈至关重要
努力这次会议将汇集研究艾滋病毒学基本方面的科学家,
直接研究治愈问题的调查人员基于免疫的消除受感染细胞的策略是一种有效的方法。
许多治疗战略的重要组成部分,为召开联合会议提供了逻辑联系,
艾滋病毒疫苗。这种配对将提供一个独特的机会,将基础和翻译
免疫学家和病毒学家考虑治愈艾滋病毒感染的挑战性目标。除了联合
会议重点关注令人兴奋的新发展,在抗体和T细胞对艾滋病毒的反应研究,
新技术,将有助于艾滋病毒生物学的未来研究,会议还包括艾滋病毒的基本机制
整合和转录控制,逆转潜伏期和消除感染细胞的策略,以及试验
新的治疗策略在动物模型和患者的艺术。这次会议的目标是带来
一群致力于功能性治疗和根除艾滋病毒的基础科学家和应用科学家,
不仅要更好地了解艾滋病毒治疗策略,而且要了解新兴技术,
这些方法将导致最终从感染者身上根除艾滋病毒。
英文摘要
ABSTRACT
Support is requested for a Keystone Symposia conference entitled HIV Pathogenesis and Cure, organized by
Drs. Robert F. Siliciano, Carine M. Van Lint and Romas Geleziunas. The conference will be held in Keystone,
Colorado from March 22-26, 2020.
Human Immunodeficiency Virus type 1 (HIV) is the cause of a global pandemic that has a very high mortality
rate, with an estimated 35 million deaths to date. In addition, another 37 million people are currently living with
HIV infection and will likely succumb from acquired immune deficiency syndrome (AIDS) without lifelong
antiretroviral therapy (ART). Optimal ART can halt viral replication, thereby preventing disease progression and
allowing immune reconstitution. However, ART is not curative due the persistence of a latent form of the virus.
This latent form is the major barrier to cure and the subject of an intense international research effort. Along
with efforts to develop an HIV vaccine, targeting the HIV latent reservoir is a major priority for AIDS research.
Achieving a better understanding of the basic biology of HIV infection is likely to be essential to HIV cure
efforts. This conference will bring together scientists studying basic aspects of HIV virology as well as
investigators working directly on the cure problem. Immune-based strategies to eliminate infected cells are an
important component of many cure strategies, providing a logical connection to hold the joint conference on
HIV Vaccines. This pairing will provide a unique opportunity to bring together basic and translational
immunologists and virologists to consider the challenging goal of curing HIV infection. In addition to joint
sessions focusing on exciting new developments in the study of antibody and T cell responses to HIV and
novel technologies that will aid future studies of HIV biology, sessions also include basic mechanisms of HIV
integration and transcriptional control, strategies for reversing latency and eliminating infected cells, and trials
of novel cure strategies in animal models and in patients on ART. The goal of this conference is to bring
together an amalgamation of basic and applied scientists working on functional cures and eradication of HIV in
an effort to not only better understand HIV treatment strategies but also the emerging technologies and
approaches that will lead to the eventual eradication of HIV from infected individuals.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Bioenergetics in Health and Diseases
-
批准号:10609120
-
项目类别:
-
资助金额:$1.74万
-
财政年份:2023
-
负责人:Thale Cross Jarvis
-
依托单位:
Autophagy and Neurodegeneration: Mechanisms to Therapies
-
批准号:10608666
-
项目类别:
-
资助金额:$1.5万
-
财政年份:2023
-
负责人:Thale Cross Jarvis
-
依托单位:
Adipose Tissue: Energizing Good Fat
-
批准号:10609127
-
项目类别:
-
资助金额:$2.02万
-
财政年份:2023
-
负责人:Thale Cross Jarvis
-
依托单位:
Cancer Neoantigens, Vaccines and Viruses
-
批准号:10233861
-
项目类别:
-
资助金额:$0.5万
-
财政年份:2022
-
负责人:Thale Cross Jarvis
-
依托单位:
Small Regulatory RNAs: From Bench to Bedside
-
批准号:10462420
-
项目类别:
-
资助金额:$0.5万
-
财政年份:2022
-
负责人:Thale Cross Jarvis
-
依托单位:
Engineering Multi-Cellular Living Systems
-
批准号:10462913
-
项目类别:
-
资助金额:$1.5万
-
财政年份:2022
-
负责人:Thale Cross Jarvis
-
依托单位:
Gut-Brain Axis
-
批准号:10467819
-
项目类别:
-
资助金额:$1.72万
-
财政年份:2022
-
负责人:Thale Cross Jarvis
-
依托单位:
Malaria: Confronting Challenges From Drug Discovery to Treatment
-
批准号:10468493
-
项目类别:
-
资助金额:$0.5万
-
财政年份:2022
-
负责人:Thale Cross Jarvis
-
依托单位:
The Human Microbiome: Ecology and Evolution
-
批准号:10391370
-
项目类别:
-
资助金额:$0.5万
-
财政年份:2022
-
负责人:Thale Cross Jarvis
-
依托单位:
Modern Phenotypic Drug Discovery: From Chemical Biology to Therapeutics
-
批准号:10468419
-
项目类别:
-
资助金额:$1.72万
-
财政年份:2022
-
负责人:Thale Cross Jarvis
-
依托单位:
Progress in Vaccine Development for Infectious Diseases
-
批准号:10467880
-
项目类别:
-
资助金额:$0.55万
-
财政年份:2022
-
负责人:Thale Cross Jarvis
-
依托单位:
Tissue Fibrosis and Repair: Mechanisms, Human Disease and Therapies
-
批准号:10462412
-
项目类别:
-
资助金额:$1.8万
-
财政年份:2022
-
负责人:Thale Cross Jarvis
-
依托单位:
Drug Delivery to the Brain: Challenges and Progress
-
批准号:10540503
-
项目类别:
-
资助金额:$1.77万
-
财政年份:2022
-
负责人:Thale Cross Jarvis
-
依托单位:
Neurocircuitry of Social Behavior
-
批准号:10540465
-
项目类别:
-
资助金额:$1.2万
-
财政年份:2022
-
负责人:Thale Cross Jarvis
-
依托单位:
Resolution of Inflammation
-
批准号:10469175
-
项目类别:
-
资助金额:$0.9万
-
财政年份:2022
-
负责人:Thale Cross Jarvis
-
依托单位:
Organoids as Tools for Fundamental Discovery and Translation
-
批准号:10469084
-
项目类别:
-
资助金额:$1.5万
-
财政年份:2022
-
负责人:Thale Cross Jarvis
-
依托单位:
Novel Approaches Against Emerging Antimicrobial Resistance
-
批准号:10391767
-
项目类别:
-
资助金额:$1.1万
-
财政年份:2022
-
负责人:Thale Cross Jarvis
-
依托单位:
Precision Genome Engineering
-
批准号:10391367
-
项目类别:
-
资助金额:$2.22万
-
财政年份:2022
-
负责人:Thale Cross Jarvis
-
依托单位:
Neuronal Control of Appetite
-
批准号:10468571
-
项目类别:
-
资助金额:$2.0万
-
财政年份:2022
-
负责人:Thale Cross Jarvis
-
依托单位:
Innate Immunity: Complement and Beyond
-
批准号:10464340
-
项目类别:
-
资助金额:$1.1万
-
财政年份:2022
-
负责人:Thale Cross Jarvis
-
依托单位:
海外基金